CSL's Seqirus, spurred on by Covid-19 mRNA vaccines, props up new unit for 'self-amplifying' shot tech
The Covid-19 pandemic has offered proof of concept for the promise of mRNA vaccines, and now CSL Behring’s Seqirus unit wants to take the next step with technology it thinks will drive the field even further into the future.
Seqirus will carve out a new business unit built around its self-amplifying mRNA vaccine work against influenza, the company said Thursday, becoming the latest major player to dive headfirst into the field after the success of the Covid-19 jabs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.